Helius Medical Technologies Aktie

NEWTOWN, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, will present at the NobleCon 19th Annual Emerging Growth Equity Conference as follows: » Mehr auf globenewswire.com

Helius Medical Technologies, Inc (NASDAQ:HSDT ) Q3 2023 Earnings Call Transcript November 9, 2023 4:30 PM ET Company Participants Michelle Gable Bilski - In-Site Communications, IR Dane Andreeff - President and CEO Jeffrey Mathiesen - CFO Conference Call Participants Nicholas Sherwood - Maxim Group Jonathan Aschoff - ROTH MKM Operator Good day, everyone. My name is Chelsea, and I will be your conference operator. » Mehr auf seekingalpha.com

-- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 -- -- Expects to report approximately $7.0 million in cash, cash equivalents and proceeds receivable from warrant exercises, extending cash runway into Q2 2024 -- -- Expects to report cash used in operating activities for the first nine months of 2023 ranging from $8.3 - $8.4 million, and for Q3 $2.4 - $2.5 million, reflecting continued focus on cash management -- » Mehr auf globenewswire.com